Exiqon A/S

Exiqon integrates RNAseq workflow in unique cloud-computing environment, XploreRNA™

Announcement of management’s and closely related parties’ transactions with securities in Exiqon A/S

Exiqon licenses validated biomarkers for prostate cancer from Aarhus University Hospital.

Redefining high risk patients with stage II colon cancer

REVISED FINANCIAL OUTLOOK 2013 DUE TO TEMPORARY SUPPLY ISSUES

CORRECTION: Exiqon A/S issues new warrants to the company’s executive board